MultiOmic Health and BIO4 Campus sign MoU to advance precision medicine

London, UK, and Belgrade, Serbia, 4 September, 2025 / MultiOmic Health Limited (“MOH”), an artificial intelligence (AI)-enabled precision medicine biotechnology company, and BIO4 Campus (“BIO4”), the Republic of Serbia's flagship biotechnology and life sciences hub, today announced the signing of a Memorandum of Understanding (MoU) to explore collaborative opportunities in biomedicine, biotechnology and bioinformatics, with a strong emphasis on AI applications.

BIO4 and MOH will work together to foster the growth of Serbia’s bioeconomy ecosystem by identifying and developing opportunities for joint research and innovation. Collaboration will initially focus on cardio-renal-metabolic diseases through integrative medical data and multi-omics approaches (genetics, epigenetics, transcriptomics, proteomics and metabolomics). This research will discover patient endotypes with distinct clinical phenotypes and omics signatures, develop AI-enabled tools to stratify those patient endotypes at earlier disease stages, and identify and validate corresponding patient stratified drug targets. These efforts will enable a more personalised approach to patient care.

Insights from this research will enable the joint development of AI-based Software as Medical Device (SaMD) and In Vitro Diagnostic (IVD) products that will optimise patient care pathways using existing treatment options. In parallel, MOH will also devise new superior treatment concepts, generate corresponding drug candidates and conduct clinical trials in partnership with its biopharma industry collaborators.

“By joining forces with BIO4 and its network of leading Serbian research and clinical institutions, we see a strong opportunity to advance the development of next-generation precision medicine solutions,” said Robert Thong, CEO of MultiOmic Health. He continued:

This collaboration reinforces our commitment to harnessing AI, data science and experimental biology to improve patient outcomes in cardio-renal-metabolic diseases globally.

“BIO4 Campus was created to be a catalyst for Serbia’s bioeconomy and an international hub for innovation,” said Smiljana Krivokuća, CEO of BIO4. “We are delighted to welcome MultiOmic Health as a partner in this mission and look forward to exploring joint opportunities that combine their expertise in precision medicine with our ecosystem’s strengths in biotechnology, clinical research and bioinformatics.”